Q3 2025 Earnings Call Transcript January 30, 2025 Takeshi Horikoshi: This is Horikoshi, the CFO. I will go through the ...

In the corresponding quarter of the previous fiscal, KEC International posted a net profit of ₹96.9 crore, the company said ...

Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...

Generic injectables maker Gland Pharma on February 3 reported a 7% rise in third-quarter profit, as lower expenses helped ...

The EBITDA margin stood at 26% in the reporting quarter versus 23.1% YoY. The results came after the close of the market ...

Aditya Birla Capital recorded revenue from operations at Rs 9381.35 crore, up 9.28 per cent as against Rs 8584.50 crore ...

The company bucked the slowdown in the discretionary space by reporting a robust performance for its mall portfolio in the ...

Titan’s revenue from operations in Q3FY25 is estimated to grow 25% YoY, while its net profit is expected to remain flat due ...

For Nifty-50 index, 23,270 and 23,100 would act as key support zones, while the 50-day SMA, 23,810 and 23,900 could be the ...

Consensus is for Q4 revenue $3.89BMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven ...

Alembic Pharmaceuticals tumbled 3.43% to Rs 905 after the company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24.

India's Divi's Laboratories reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses on customised production of chemical compounds used in ...